Search details
1.
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.
Cancer Sci
; 110(9): 2924-2932, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31336012
2.
Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Cancer Sci
; 109(10): 3245-3252, 2018 Oct.
Article
in English
| MEDLINE | ID: mdl-30058108
3.
Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Cancer Sci
; 108(3): 461-468, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-28092421
4.
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Br J Haematol
; 172(5): 745-56, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26732066
5.
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Int J Hematol
; 111(1): 57-64, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31664647
6.
Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.
Int J Hematol
; 104(5): 596-604, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27460677
Results
1 -
6
de 6
1
Next >
>>